Search results for "17-diol"

showing 7 items of 7 documents

Time-dependent changes in serum 3α-androstanediol glucuronide correlate with hirsutism scores after ovarian suppression

1995

The clinical utility of serum 3 alpha-androstanediol glucuronide level has been controversial. Among the concerns regarding its lack of utility has been the finding that suppression of serum 3 alpha-androstanediol glucuronide does not occur readily with treatment. We hypothesized that because the treatment of hirsutism requires a prolonged duration, a longer observation period is required for changes in serum 3 alpha-androstanediol glucuronide to be measured. Therefore, we studied the clinical and hormonal changes in 11 women treated for hirsutism with a gonadotropin-releasing hormone agonist (GnRH-a) for 1 year. A progressive reduction in Ferriman-Gallwey scores occurred, which was signifi…

AdultAgonistHirsutismmedicine.medical_specialtyAndrosterone glucuronidemedicine.drug_classEndocrinology Diabetes and MetabolismObservation period3-alpha-androstanediol glucuronideAndrosteroneEndocrinologyOvarian suppressionInternal medicinemedicineHumansTestosteronehirsutismTriptorelin Pamoatebusiness.industryObstetrics and Gynecologymedicine.diseaseAndrostane-317-diolEndocrinologyFemaleGlucuronidebusinessPolycystic Ovary SyndromeHormoneGynecological Endocrinology
researchProduct

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct

CCDC 970547: Experimental Crystal Structure Determination

2014

Related Article: Màrius Tarrés, Clara Viñas, Patricia González-Cardoso, Mikko M. Hänninen, Reijo Sillanpää, Vladimír Dordovič, Mariusz Uchman, Francesc Teixidor, Pavel Matejíček|2014|Chem.-Eur.J.|20|6786|doi:10.1002/chem.201402193

Space GroupCrystallography(mu~2~-119-bis(55''-(11'-commo-bis(1-cobalta-23-dicarba-closo-dodecaborate(11))))-3691215-pentaoxaheptadecane-117-diolate)-(mu~2~-acetone)-di-sodiumCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1054373: Experimental Crystal Structure Determination

2015

Related Article: Alexandre Abhervé, Samuel Mañas-Valero, Miguel Clemente-León, Eugenio Coronado|2015|Chemical Science|6|4665|doi:10.1039/C5SC00957J

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameterscatena-((415-Dimethyl-581114-tetra-azaoctadeca-241416-tetraene-217-diolato)-iron(iii) tris(mu2-36-dibromo-25-dioxy-14-benzoquinone)-chromium(iii)-manganese(ii) acetonitrile solvate)Experimental 3D Coordinates
researchProduct

CCDC 1054372: Experimental Crystal Structure Determination

2015

Related Article: Alexandre Abhervé, Samuel Mañas-Valero, Miguel Clemente-León, Eugenio Coronado|2015|Chemical Science|6|4665|doi:10.1039/C5SC00957J

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameterscatena-((415-Dimethyl-581114-tetra-azaoctadeca-241416-tetraene-217-diolato)-iron(iii) tris(mu2-36-dichloro-25-dioxy-14-benzoquinone)-chromium(iii)-manganese(ii) acetonitrile solvate)Experimental 3D Coordinates
researchProduct

CCDC 1823995: Experimental Crystal Structure Determination

2018

Related Article: Marta Mon, Rosaria Bruno, Jesús Ferrando-Soria, Lucia Bartella, Leonardo Di Donna, Marianna Talia, Rosamaria Lappano, Marcello Maggiolini, Donatella Armentano, Emilio Pardo|2018|Materials Horizons|5|683|doi:10.1039/C8MH00302E

Space GroupCrystallographyCrystal SystemCrystal Structurecatena-[estra-1(10)24-triene-317-diol tris(mu-22'-[(12-dioxoethane-12-diyl)diimino]bis(3-hydroxypropanoato))-tetrakis(mu-aqua)-bis(mu-hydroxo)-calcium-hexa-copper(ii) acetonitrile solvate hexahydrate]Cell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1054374: Experimental Crystal Structure Determination

2015

Related Article: Alexandre Abhervé, Samuel Mañas-Valero, Miguel Clemente-León, Eugenio Coronado|2015|Chemical Science|6|4665|doi:10.1039/C5SC00957J

catena-((415-Dimethyl-581114-tetra-azaoctadeca-241416-tetraene-217-diolato)-gallium(iii) tris(mu2-36-dibromo-25-dioxy-14-benzoquinone)-chromium(iii)-manganese(ii) acetonitrile solvate)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct